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Abstract  36 
 37 
Context: A common polymorphism in the gene encoding the activating deiodinase (Thr92Ala-D2) is 38 
known to be associated with quality of life in millions of patients with hypothyroidism and with several 39 
organ-specific conditions. This polymorphism results in a single amino acid change within the D2 mole-40 
cule where its susceptibility to ubiquitination and proteasomal degradation is regulated.  41 
Objective: To define the molecular mechanisms underlying associated conditions in carriers of the 42 
Thr92Ala-D2 polymorphism. 43 
Design, Setting, Patients: Microarray analyses of nineteen postmortem human cerebral cortex samples 44 
were performed to establish a foundation for molecular studies via a cell model of HEK-293 cells stably 45 
expressing Thr92 or Ala92 D2. 46 
Results: The cerebral cortex of Thr92Ala-D2 carriers exhibits a transcriptional fingerprint that includes 47 
sets of genes involved in CNS diseases, ubiquitin, mitochondrial dysfunction (chromosomal genes encod-48 
ing mitochondrial proteins), inflammation, apoptosis, DNA repair and growth factor signaling. Similar 49 
findings were made in Ala92-D2-expressing HEK-293 cells and in both cases there was no evidence that 50 
thyroid hormone signaling was affected, i.e. the expression level of T3-responsive genes was unchanged, 51 
but that several other genes were differentially regulated. The combined microarray analyses (brain/cells) 52 
led to the development of an 81-gene classifier that correctly predicts the genotype of homozygous brain 53 
samples. In contrast to Thr92-D2, Ala92-D2 exhibits longer half-life and was consistently found in the 54 
Golgi. A number of Golgi-related genes were down-regulated in Ala92-D2-expressing cells but were nor-55 
malized after 24h-treatment with the antioxidant N-acetylecysteine.  56 
Conclusions: Ala92-D2 accumulates in the Golgi, where its presence and/or ensuing oxidative stress dis-57 
rupts basic cellular functions and increases pre-apoptosis. These findings are reminiscent to disease mech-58 
anisms observed in other neurodegenerative disorders such as Huntington’s disease, and could contribute 59 
to the unresolved neurocognitive symptoms of affected carriers.  60 
 4 
Introduction 61 
 62 
Hypothyroidism is found in about 4.6 percent of the U.S. population age 12 and older (1). The current 63 
standard of care for these patients is treatment with daily tablets of the long-lived pro-thyroid hormone 64 
(TH), levothyroxine (L-T4). T4 is subsequently activated to T3 outside of the thyroid parenchyma via the 65 
deiodinases, i.e. D1 and D2. Unfortunately therapy with L-T4 alone does not resolve symptoms in all hy-66 
pothyroid patients, with approximately 12% of the patients remaining symptomatic despite normalization 67 
of serum TSH and TH levels (2, 3). Impaired cognition, fatigue and difficulty losing weight are the main 68 
residual symptoms of these patients, for which we lack understanding and have no mechanistic explana-69 
tion.  70 
 71 
A prevalent Thr92Ala-D2 polymorphism (between 12-36% of the population are homozygotes (4)) has 72 
been identified that results in a single amino change at position 92 within an 18 amino acid loop that con-73 
trols D2 ubiquitination for proteasomal destruction (5, 6). Hypothyroid individuals carrying this polymor-74 
phism were found to have a preference for a therapy that includes T3 vs. monotherapy with L-T4 alone 75 
(7), suggesting defective Ala92-D2 catalysis. In addition, the Thr92AlaD2 polymorphism has been asso-76 
ciated with conditions aside from symptomatic hypothyroidism such as mental retardation (8), low IQ (9) 77 
and bipolar disorder (10); this supports the hypothesis that Ala92-D2-expressing is disruptive aside from 78 
impaired T4 activation. 79 
 80 
Here we used a multifaceted strategy to define the molecular foundation of the clinical syndromes associ-81 
ated with the Thr92AlaD2 polymorphism. There are unique modifications in the cellular transcriptome 82 
identified in human brains homozygous for the polymorphism that are independent of TH signaling. 83 
These transcriptional changes included upregulation of processes related to the mitochondria, Golgi appa-84 
ratus/ER transport, oxidative stress and apoptosis, suggesting a molecular basis underlying cerebral symp-85 
tomatology in affected individuals. A cellular model revealed that Ala92-D2 protein exhibits a longer 86 
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half-life and, as opposed to Thr92-D2, can be found in the Golgi apparatus. Cells expressing Ala92-D2 87 
also exhibited alteration in expression of Golgi markers, a finding that absolved with antioxidant treat-88 
ment. Notably, in both the human brain and cell models there is molecular and physiological evidence of 89 
dysregulation in EGF receptor signaling, a pathway known to be altered in oxidative stress (11) and play 90 
an important role in cognitive development (12) and function (13-16). 91 
 92 
Materials and Methods 93 
 94 
Human Brain Samples 95 
 96 
The University of Miami (UM) Brain Endowment Bank provided genomic DNA and brain tissue samples 97 
from postmortem human donors; protocols at UM were IRB-approved. Cause of death was limited to ac-98 
cident or sudden cardiac death without medical intervention or prolonged agonal state. Postmortem inter-99 
val at specimen collection was <24 hours, brain pH (quality measure) was >6.0. Genomic DNA from 95 100 
brain samples was genotyped for the Thr92AlaD2 polymorphism by sequence analysis according to pre-101 
viously published methods (17). Brain samples from 19 patients without known thyroid or neurologic dis-102 
ease (six from homozygous Thr92-D2, seven heterozygotes and six homozygotes for Ala92-D2) were 103 
matched by age (ANOVA p = 0.46), sex (male), race (Caucasian) and BMI (ANOVA p = 0.66) and cho-104 
sen for further studies. Homogenous samples were dissected from frozen coronal blocks based on surface 105 
and cytoarchitectural landmarks from Brodmann’s Area 38 (temporal cortex) by neuroanatomist and 106 
stored at -80°C.  107 
 108 
Microarray Studies of Human Brain 109 
 110 
RNA was extracted (RNeasy Lipid Tissue Mini Kit, Qiagen) and cDNA generated (First Strand cDNA 111 
Synthesis Kit, Roche). RNA from all 19 human brain samples from each of the three genotypes (Ala92-112 
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D2 homozygotes, Hets, and Thr92-D2 homozygotes) was analyzed by microarray at the Joslin Diabetes 113 
Center Genomics Core Laboratory (Boston, MA). Gene expression was evaluated using Genechip Human 114 
Gene 2.0 ST arrays (Affymetrix, Santa Clara, CA) which utilizes a whole-transcript design to assess 115 
>30,000 coding genes. Gene expression data was preprocessed using Affymetrix Expression Console. 116 
Differential expression analysis was performed in Affymetrix Transcriptome Analysis Console to identify 117 
individual genes demonstrating enrichment in three comparisons: Ala92-D2 homozygotes vs. Thr92-D2 118 
homozygotes (Table S2), Ala92-D2 homozygotes vs. Hets and Hets vs. Thr92-D2 homozygotes. Expres-119 
sion values (signal) of individual genes were log2 transformed. One-way ANOVA was used to calculate 120 
p-values for each fold change (linear); multi-testing correction was then performed using the Benjamini-121 
Hochberg Step-Up FDR-controlling procedure for all the expressed genes. Genes were considered statisti-122 
cally significant with an ANOVA p-value <0.05. A custom heat map displaying expression values of the 123 
25 with the highest and lowest fold change was generated (HeatMapViewer, GenePattern, Broad Insti-124 
tute). 125 
 126 
Gene ontology analysis was used to determine differences in gene sets between phenotypes (Gene Set En-127 
richment Analysis (GSEA), Broad Institute). Expression values for all genes from all 19 brain samples 128 
were used; no filter was applied to eliminate genes with low expression. GSEA included calculation of 129 
enrichment scores (ES), estimation of significance level of ES (nominal p-value), and adjustment for mul-130 
tiple hypothesis testing including the normalized enrichment score (NES) and false discovery rate (FDR). 131 
Gene sets with an FDR ≤25% were limited (3) and given the goal of hypothesis generation, a nominal p-132 
value of <1% was chosen to indicate significance. Core enrichment of individual genes within these gene 133 
sets was defined as those genes contributing to the leading-edge subset. All individual genes demonstrat-134 
ing core enrichment within the enriched gene sets were further considered by investigators (investigator 135 
analysis); this consisted of searches in publically available databases (PubMed, UniProt). A heatmap of 136 
the top 50 ranking genes from each genotype was generated by GSEA. GSEA was also applied to an in-137 
vestigator-generated custom gene set of known T3-responsive genes (18, 19). 138 
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 139 
Pathway analysis was performed with Ingenuity Pathway Analysis (IPA). The signal intensity values 140 
from the entire microarray dataset (all genes, all 19 samples) were used to identify canonical pathways 141 
altered between the three genotypes. When viewing the EGF Signaling pathway alone (p <0.001, ratio 142 
50/56 genes), individual genes demonstrating alteration in our dataset were highlighted in an IPA-gener-143 
ated pathway diagram. 144 
 145 
Class prediction was performed (WeightedVoting, GenePattern) via two approaches. First the algorithm 146 
created a 10-gene classifier that was able to correctly predicted the genotypes of 12/12 samples; 2 of these 147 
10 genes were SNORD16 and TRAPPC4. Then, the weighted voting prediction algorithm was used with 148 
an investigator-derived list of 79 genes as a classifier, where 11/12 sample genotypes were correctly pre-149 
dicted. Lastly, the 79-gene classifier was supplemented with the addition of SNORD16 and TRAPPC4 150 
and applied to the microarray data from the Thr92-D2 and Ala92-D2 homozygotes. 151 
 152 
Generation of stable cell lines and cell culture 153 
 154 
HEK-293 cells (American Type Culture Collection, Manassas, VA) were cultured in 150-mm dishes with 155 
DMEM (Life Technologies) supplemented with 10% fetal bovine serum (FBS). Unless noted otherwise, 156 
all experiments were performed with 10% FBS-containing media. In particular, HEK-293 cells were cho-157 
sen for this experiment as they express low levels of the deiodinases (20) and TR (21) and because they 158 
have certain properties consistent with neuronal lineage (22, 23).   159 
 160 
The 6×His-CysD2-YFP (D2) vector was created fusing enhanced yellow fluorescent protein (EYFP) in 161 
frame to the C terminus of 133Cys/266Cys (CysD2) mutant human D2. The D2-EYFP cassette was in-162 
serted in-frame between EcoRI-NotI of pcDNA™4/ HisMax C (Invitrogen). The Thr92Ala (T92A) mu-163 
tant of 133Cys/266Cys was generated by overlap extension PCR. HEK-293 cell lines stably expressing 164 
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wild type Thr92-D2HY or polymorphic Ala92-D2HY were established by transfecting 2.5 μg of His-D2-165 
YFP vector using Lipofectamine 2000 reagent (Invitrogen) according to manufacturer's instructions. 166 
D2HY-expressing clones of HEK-293 cells were selected 48h after transfection by antibiotic resistance 167 
(Zeocin, 300 μg/mL) for 2 weeks. The control yellow fluorescent protein (YFP)-expressing vector has 168 
been described elsewhere (24); these D2HY-expressing cells exhibit similar properties compared to cells 169 
with native D2 (24). Some cells were grown to confluence and then treated with 1mM N-acetylecysteine 170 
(NAC, Sigma) or 1M trimethylamine-N-oxide (TMAO, Sigma) for 24 hours. In addition, some cells were 171 
treated with brefeldin A (BFA, Tocris), dissolved in abs ethanol for 30 minutes at 0.5ug/mL and then pro-172 
cessed for electron microscopy (EM). 173 
 174 
Flow Cytometry 175 
 176 
BD FACSCalibur flow cytometer was used for these studies. For apoptosis, Annexin V-PE apoptosis de-177 
tection kit (eBioscience) was used for annexin V cell surface staining per manufacturer’s protocol. For 178 
cell cycle analysis, cells were collected, washed and resuspended. -20°C absolute ethanol was added in 179 
dropwise manner to the cell while vortexing. HEK-293 cells were fixed for 1h at 4°C. After washing 180 
twice, 40 g/ml propidium iodide and 1 g/ml RNase were added and incubated 3h at 4°C and subse-181 
quently analyzed by FACS. All of the FACS data were obtained after correct compensation setting using 182 
single labeled control. For cell size analysis, forward scatter was used as a measure of relative size. 183 
 184 
Co-culture of Thr92-D2HY and Ala92-D2HY-expressing cells with T3-responsive HeLa cells  185 
 186 
As a positive control, HeLa cells were grown to confluence in solutions of 0nM T3 or 100nM T3 (19) and 187 
harvested for RT-qPCR of known T3-responsive genes, BCL3 and SPOT14; both genes were signifi-188 
cantly increased in the 100nM confirming T3-responsiveness in our system. Then, Thr92-D2HY and 189 
Ala92-D2HY HEK cells were grown to confluence in the upper chamber of a Transwell permeable support 190 
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(Corning) above, but not in physical contact with, highly T3-responsive HeLa cells (American Type Cul-191 
ture Collection) in 10% FBS. HeLa cells were harvested, RNA extracted and processed for RT-qPCR of 192 
T3-responsive genes. 193 
 194 
Immunofluorescence 195 
 196 
Cells were plated on poly-D-lysine-coated chamber slides and fixation, imaging and colocalization were 197 
performed as previously described (25). D2 was imaged with 1:500 YFP (Rockland immunologicals) 198 
and 1:1000 nuclear lamin (Cell Signaling). For the Golgi immunofluorescence, cells were grown on 199 
culture slide until confluent. After fixation in 4% paraformaldehyde (Electron Microscopy Science) for 30 200 
min, cells were permeabilized by 0.5% Triton X-100 and subsequently blocked by Fish Skin Gelatin (Bi-201 
otum). GM130 antibody (CellSignaling technology) and antiGFP antibody (Rockland immunologicals) 202 
were added at 1ug/ml concentration at 4C overnight. Secondary antibodies (Life Technologies) were in-203 
cubated for an hour and made into slide using SloFade Gold mounting medium (Life Technologies). Im-204 
ages were acquired using Nikon eclipse Ti microscope with C1 confocal system. Images were subse-205 
quently analyzed by NISelement AR or ImageJ software 206 
 207 
For immunofluorescence after CHX treatment, each chamber was fixed as previously described (26) and 208 
then incubated in a mixture of mouse Na+/K+ATPase antiserum (Santa Cruz, (M7-PB-E9) at 1:250 dilu-209 
tion and rabbit GFP antiserum at 1:10000 dilution in PBS containing 2% normal horse serum and 0.2% 210 
sodium azide (antiserum diluent) for 2 days at 4°C. After rinses in PBS, the cells were incubated in bioti-211 
nylated donkey anti-mouse IgG for 2h (1:500; Jackson Immunoresearch Lab, West Grove, PA) followed 212 
by treatment in avidin–biotin–peroxidase complex (ABC Elite; 1:1000; Vector Laboratories, Burlingame, 213 
CA) in 0.05M Tris buffer for 1 h at room temperature. Signal of Na+/K+ATPase was amplified with bioti-214 
nylated tyramide for 10 min using the TSA amplification kit (Perkin Elmer Life and Analytical Sciences, 215 
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Waltham, MA) according to the manufacturer’s instruction. The cells were incubated in Streptavidin Cy5 216 
(1:250; Jackson Immunoresearch Lab) and Alexa 555 conjugated anti-rabbit IgG (1:500, Invitrogen) for 217 
2h at room temperature. Sections were mounted on glass slides and coverslipped with Vechtashield 218 
Mounting medium (Vector). Imaging was performed on a Zeiss LSM 780 Confocal Microscope. 219 
 220 
Ultrastructural studies 221 
 222 
2x105 Thr92-D2HY or Ala92-D2HY stably expressing HEK-293 cells were plated on 2-well Permanox 223 
plastic chamber slides (Lab-Tek). The next day, cells were treated with 100uM CHX or DMSO as vehicle 224 
for 2h and fixed in chamber slides with the mixture of 3% PFA and 1% glutaraldehyde in 0.1M phosphate 225 
buffer (PB) pH7.4 (PB) at 37°C for 1h. After 3 washes for 2 min with 0.01M PBS pH 7.4, the cells were 226 
cryoprotected in 30% sucrose in PBS for 30 min at room temperature and then, quickly frozen over liquid 227 
nitrogen. The cells were washed again 3x with 0.01M PBS and then treated with 2% normal horse serum 228 
(NHS; in PBS) for 20 min. Pretreated cells were covered with rabbit anti-GFP serum (1:10,000) diluted in 229 
2% NHS in PBS for 2 days at 4°C. After rinsing in PBS and in 0.1% cold water fish gelatin  +1% bovine 230 
serum albumin (BSA) in PBS, the cells were incubated in donkey anti-rabbit IgG conjugated with 0.8 nm 231 
colloidal gold (Electron Microscopy Sciences, Fort Washington, PA) diluted at 1:100 in PBS containing 232 
0.1% cold water fish gelatin and 1% BSA overnight at 4°C. After rinsing in PBS and fixed with 1.25% 233 
glutaraldehyde in 0.1M PB at room temperature for 10 min. After rinsing in PBS and in Aurion buffer for 234 
20 min, gold particles were silver intensified using the Aurion R-Gent SE-LM Kit (Amersham–Pharmacia 235 
Biotech UK, Buckinghamshire, UK). The cells were washed 3x for 2 min in 0.2M sodium citrate, pH7.5 236 
followed by washes in 0.1M PB. Cells were treated with 1% osmium tetroxide in 0.1M PB for 20 min at 237 
4°C, followed by treatment with 2% uranyl acetate in 70% ethanol for 10 min. After dehydration in an 238 
ascending series of ethanol and acetonitrile, the cells were embedded in Durcupan ACM epoxy resin 239 
(Fluka) in a gelatin capsule, and polymerized at 56°C for 2 days.  Serial 60–70 nm thick utlrasections 240 
were cut with Leica ultracut UCT ultramicrotome (Leica Microsystems, Wetzlar, Germany). The ultrathin 241 
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sections were mounted onto Formvar-coated single slot grids, contrasted with 2% lead citrate and exam-242 
ined with a Jeol-100 C transmission electron microscope. 243 
 244 
Western blot quantitation 245 
 246 
Western blot was performed as 30g of total protein was resolved on a 4-12% SDS-PAGE gel. The sam-247 
ples were transferred to PVDF transfer membrane (Immobolin-FL, Millipore), incubated with various an-248 
tibodies overnight at 4C and subsequently quantitated by using the LiCOR Odyssey instrument with Od-249 
yssey Image Studio software simultaneously (D2 vs. actin or tubulin) using different infrared channels. 250 
 251 
Isolation of subcellular membrane fractions 252 
 253 
Cells were collected, re-suspended in PBS solution with Complete-mini EDTA-free protease inhibitor 254 
(Roche) at 4°C. Cells were homogenized by 10 passages through a ball homogenizer (Isobiotec) at 10 μm 255 
clearance. Homogenates were centrifuged for 10 min at 800×g. The resulting nuclear (N′) pellet was 256 
washed twice with ice-cold PBS by centrifugation, while the supernatant fraction, containing cytosolic 257 
membranes and the cytosol, was designated as lysate and used for D2 activity assay. For western blot, nu-258 
clear and lysate samples were prepared using nonionic detergent Triton X-100. 293 cells were treated 259 
with 0.5% Triton X-100 at 4°C and centrifuged at 800×g for 10 min to isolate nuclear (N) fraction. The 260 
supernatant after centrifugation, which contained Triton X-100 soluble membranes and cytosol, was des-261 
ignated as lysate. 262 
 263 
D2 activity assay 264 
 265 
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D2 activity was assayed in cell lysates and nuclear fractions using 150g cell sonicated protein incubated 266 
in PE-EDTA pH 7.35 buffer at 37C in the presence of 1uM 125I-T4 and 20 uM DTT for 2h (19). Assay 267 
was terminated by addition of TCA and horse serum and 125I released quantified in a gamma counter. 268 
Background activity was measured for each sample in the presence of 100uM 125I-T4. Results are ex-269 
pressed as fmols 125I/min/mg protein.  270 
 271 
Microarray studies of cultured cells 272 
 273 
RNA was extracted from confluent cells from each group (RNeasy kit, Qiagen). Microarray data from 274 
samples from three plates each of the three cell types (YFP, Thr92-D2HY and Ala92-D2HY) were collected 275 
and analyzed as above. In addition, hierarchical clustering analysis was performed (HierarchicalCluster-276 
ing, GenePattern) using the pairwise average-linkage clustering method and Pearson correlation column 277 
distance measure to generate a dendogram. Creation and application of the class predictor (classifier) was 278 
performed (KNNXValidation, GenePattern) where the k-nearest-neighbors (KNN) class prediction algo-279 
rithm was used to run class prediction iteratively against the dataset from all three cell genotypes. The 280 
PredictionResultsViewer and FeatureSummaryViewer modules were then used to obtain values for the 281 
absolute error rate (incorrect cases/total cases) and ROC error rate (receiver operating characteristic; frac-282 
tion of true positives versus the fraction of false positives) and to view the genes comprising the classifier. 283 
To compare overlap between gene expression from the brain and cell microarray GSEAs, individual 284 
genes demonstrating core enrichment within the enriched gene sets were entered into VENNY (http://bio-285 
infogp.cnb.csic.es/tools/venny/index.html) where Venn diagrams were used to identify common genes. 286 
 287 
RT-qPCR 288 
 289 
RT-qPCR (StepOnePlus Real-Time PCR Detection System, Applied Biosystems) using Taqman reagents 290 
(Applied Biosystems) was performed on human brain samples with the following conditions: 2 min at 291 
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50°C followed by 10 min at 95°C, 15 sec at 95°C, 1 min at 60°C x 40. Standard curves consisted of 5 292 
points of serially diluted cDNA from all samples. Cyclophilin A (CycloA) was used as an internal control 293 
gene and there was no difference in CycloA expression between the three genotypes. The coefficient of 294 
correlation (r2) was > 0.98 for all curves; amplication efficiency ranged from 90-110%. Results expressed 295 
as the ratio of target mRNA to CycloA mRNA. For HEK-293 cell PCR,18s was used for housekeeping. 296 
 297 
In HeLa cells, BCL3 and SPOT14 were measured by RT-qPCR using SYBR green Fastmix (Quanta Bio-298 
science) with the following conditions: 20 sec at 95°C, 3 sec at 95°C and 30 sec at 60°C x 40, and 15 sec 299 
at 95°C followed by 1 min at 60°C and 15 sec at 95°C. Standard curve, r2 and amplification efficiency 300 
were as above  301 
  302 
Statistics 303 
 304 
All data were analyzed using PRISM software (GraphPad). Unless otherwise indicated, data represent 305 
mean ± SEM, comparisons between two groups were analyzed with a two-tailed Student’s t test and com-306 
parisons between more than two groups were carried out by ordinary one-way ANOVA. A p-value <0.05 307 
was considered significant. 308 
 309 
Analysis of the human brain RT-qPCR data was done using Agilent Genespring GX version 12.6. The 310 
probeset data was log2 transformed and grouped according to Thr92-D2 homozygote, Het, and Ala92-D2 311 
homozygous status. Each individual gene was compared using fold change between the three groups pair-312 
wise, selecting those genes that had an absolute fold change ≥1.5 in at least one of the three pairwise 313 
group comparisons.  Each gene other than the mutant DIO2 was also correlated with DIO2 using Pear-314 
son’s correlation. For clustering analysis, the data was further normalized to means of normal samples. 315 
This normalized gene expression data was clustered gene-wise using an unsupervised hierarchical cluster-316 
ing algorithm, with Euclidean distance metric and Ward’s linkage rule. 317 
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 318 
Results  319 
 320 
Analysis of the human brain transcriptome in patients carrying the Thr92-D2 polymorphism 321 
 322 
The effects of the D2 polymorphism in humans were analyzed in the cerebral cortex of recently deceased 323 
adult accident/sudden death victims without known neurological or thyroid disease. Genotyping on brain 324 
samples from 95 donors revealed 24 homozygous for the Thr92AlaD2 polymorphism, 52 heterozygous 325 
and 25 normal patients; these frequencies are in Hardy-Weinberg equilibrium. Brain samples from 19 326 
male Caucasian donors (six samples from homozygote Thr92-D2, seven heterozygotes and six homozy-327 
gotes for Ala92-D2) were matched by age and BMI and chosen for further studies (Table S1). Homoge-328 
nous samples from Brodmann’s Area 38 of the temporal cortex were evaluated for gene expression. 329 
Given the diverse array of phenotypes exhibited by carriers of the polymorphism and the findings of nor-330 
mal catalytic activity of the D2 enzyme (27, 28), we hypothesized that this alteration could result in non-331 
catalytic cellular consequences. Thus an unbiased whole-transcript microarray approach was used to as-332 
sess the potential impact of the polymorphism and generate hypotheses regarding the mechanism of dys-333 
function in Ala92-D2 expression. 334 
 335 
First, differentially expressed individual genes were identified by comparing the data from three geno-336 
types: Ala92-D2 homozygotes vs. Thr92-D2 homozygotes, Ala92-D2 homozygotes vs. heterozygotes 337 
(Het), and Hets vs. Thr92-D2 homozygotes. Differences in gene expression between the Ala92-D2 homo-338 
zygote vs. Thr92-D2 homozygote comparison were considered at a p-value <0.05 (Fig. 1A). As a result, 339 
839 named genes were found to be differentially expressed where 110 of these were altered at a fold 340 
change >1.3 or <-1.3 (Table S2). A heat map incorporating the 25 genes with the highest or lowest ex-341 
pression values by fold change between these two genotypes was built (Fig. 1B); it is notable that despite 342 
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statistical significance between the two genotypes, the expression of some genes is heterogeneous reflect-343 
ing their multifactorial regulation. 344 
 345 
In order to evaluate the physiologic context of the transcriptional footprint left by Ala92-D2-expression, 346 
the microarray data were then analyzed by GSEA (29, 30). When performed in the Ala92-D2 vs. Thr92-347 
D2 samples, GSEA revealed enrichment of 18 gene sets at a nominal p-value <0.05 (3 of which were ad-348 
ditionally enriched at an FDR <0.25) and downregulation of 10 gene sets at a nominal p-value <0.05 (Ta-349 
ble S3). Within these gene sets a total of 382 genes demonstrated core enrichment; heat map of the 50 top 350 
genes for each phenotype was generated (Fig. 1C). Investigator analysis of transcripts identified by GSEA 351 
showed that genes enriched in Ala92-D2 homozygotes were primarily related to apoptosis, oxidation-re-352 
duction, mitochondrial function, carbohydrate metabolism, ribosome components, inflammation, li-353 
pid/fatty acid metabolism, cytoskeleton structure, Golgi/ER transport, DNA repair and transcription regu-354 
lation. Genes downregulated in Ala92-D2 homozygotes were related to cell growth, cell cycle control, 355 
phospholipid maintenance, EGFR signaling, phosphatidylinositol and lipoprotein metabolism.  356 
 357 
To test whether carriers of the Ala92-D2 genotype exhibited changes in TH signaling we examined mi-358 
croarray data for the expression level of a set of typical T3-responsive genes (Table S4) (18, 19) and 359 
found no significant differences by GSEA (Fig. S1A). Next, expression data were processed through 360 
pathway analysis software to identify cellular pathways that altered at the p<0.05 level when the three 361 
genotypes are assessed. Many of the top pathways exhibiting significant changes in at least 60% of their 362 
genes shared overlapping functional significance (Fig. 1D); Huntington’s Disease Signaling was the top 363 
canonical pathway identified (ratio of genes affected 180/225, p-value <0.0001). 364 
 365 
A cell model to assess the impact of Thr92-D2 expression  366 
 367 
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Findings from the human brain microarray supported an association between gene expression pattern and 368 
genotype and thus served as grounds for further investigation using a cell model. HEK-293 cells were 369 
chosen as suitable candidates for the model as they exhibit many features of neuronal lineage (22, 23) and 370 
are known for lacking in deiodinase expression (20); these cells also lack in TR, which eliminates cell 371 
changes due to altered TH signaling (21). Thus, we used a previously characterized HEK-293 cell model 372 
that stably expresses a His/YFP-doubled tagged Sec133Cys-Thr92D2 (Thr92-D2HY) (24). In this setting, 373 
Thr92-D2HY exhibited similar cellular properties as endogenously expressed D2 and the host cells were 374 
not adversely affected when compared to cells stably expressing YFP (24). Here we observed that stable 375 
expression of Ala92-D2HY protein also did not result in gross cellular phenotypic alterations (Fig. 2A-B). 376 
Ala92-D2HY sorted predominantly to the ER and no differences were observed in cell size as assessed by 377 
flow cytometry (Fig. S2A-B), cell cycle (Fig. S2C) or cell duplication time (Fig. S2D) when compared 378 
with cells stably expressing Thr92-D2HY.  379 
 380 
Both Thr92-D2HY and Ala92-D2HY are found in the nucleus and ER but only Ala92-D2HY has a longer 381 
half-life and can be found in the Golgi apparatus 382 
 383 
The Thr for Ala substitution in the D2 molecule is in the instability loop (5, 6), possibly affecting D2 384 
turnover rate and other functions of Ala92-D2HY-expressing cells. Thus, we first looked at the rate of dis-385 
appearance of Ala92-D2HY protein following exposure to its natural substrate T4 that accelerates D2 ubiq-386 
uitination and proteasomal degradation (31). Notably, whereas there was progressive loss of Thr92-D2HY 387 
after T4 was added to the medium, the abundance of the Ala92-D2HY protein remained largely unaffected 388 
by T4, suggesting impaired ubiquitination/degradation (Fig. S3A-B). Indeed, we used cycloheximide 389 
(CHX) to arrest protein synthesis and found that Ala92-D2HY had a longer half-life (~33 vs. ~13 min) 390 
when compared to Thr92-D2HY protein (Fig. 2C-D). This was confirmed with immunofluorescent locali-391 
zation where more Ala92-D2HY protein is seen after CHX treatment (Fig. 2E-F).  392 
 393 
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A more detailed analysis of the immunofluorescence microscopy images shows that D2HY protein can 394 
also be found closely associated with the nucleus (Fig. 2A-B). In fact, when stained for nuclear lamin 395 
(Fig. S3E-F), co-localization of D2HY proteins was demonstrated but no differences were observed be-396 
tween Thr92-D2 and Ala92-D2 proteins (Pearson’s coefficient: 0.48 ± 0.02 vs. 0.49 ± 0.03; n=10). The 397 
presence of D2 in the ER and nucleus was also detected using EM, but no differences were observed be-398 
tween Thr92-D2 and Ala92-D2 proteins in these cellular compartments (Fig. 2G-J). Next we isolated the 399 
nuclear fraction and detected Thr92-D2 and Ala92-D2 proteins by western analysis, both types of D2 dis-400 
appearing with CHX treatment (Fig. S3C). Notably, nuclear D2 is catalytically active where its activity is 401 
not influenced by the polymorphism (Fig. S3D).  402 
 403 
A remarkable new finding of the present studies is the observation with EM that only Ala92-D2HY could 404 
be identified in the Golgi apparatus (Fig. 3A-C). Even when cells are depleted of D2 by treatment with 405 
CHX, D2 was still consistently observed in the membranes of the Golgi apparatus (Fig. S4). Structural 406 
differences in Golgi as assessed by immunofluorescence were apparent under these conditions with Golgi 407 
in Ala92-D2HY-expressing cells exhibiting a circular configuration as opposed to its normal ribbon mor-408 
phology (Fig. 3D-F). These findings were also documented by EM but only when the Golgi apparatus in 409 
Ala92-D2HY-expressing cells was further stressed with BFA treatment (Fig. 3G-I, M-O). 410 
 411 
Defining a transcriptional fingerprint of Ala92-D2HY expression in cultured cells 412 
 413 
Given that fundamental biological differences exist between Thr92-D2HY and Ala92-D2HY that could un-414 
derlie the transcriptional patterns observed in affected human brains, we next turned to an unbiased mi-415 
croarray approach to assess the impact of Ala92-D2HY expression in our cell model. Differential expres-416 
sion analysis was performed to identify individual genes altered in the three cell lines: Ala92- D2HY vs. 417 
Thr92- D2HY, Ala92- D2HY vs. YFP, Thr92 D2HY vs. YFP. A volcano plot for Ala92- D2HY- vs. Thr92- 418 
D2HY-expressing cells allowed for visualization of the differences in gene expression at a p-value <0.05 419 
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(Fig. 4A). This resulted in 3155 named genes differentially expressed where 263 of these were altered at a 420 
fold change >1.3 or <-1.3 (Table S5). The 50 most affected genes by the Ala92-D2HY expression were 421 
plotted in a heat map (Fig. 4B).  422 
 423 
We then performed a hierarchical clustering analysis (32). The resulting dendogram utilized the expres-424 
sion profiles of 6643 genes within these phenotypic contexts and indicated that the gene expression pat-425 
tern appropriately clustered the three samples in groups with their respective phenotypes and that Ala92-426 
D2 and Thr92-D2 clusters exhibited a more similar gene expression pattern than the YFP controls (Fig. 427 
4C). Also, we used class prediction analysis of the microarray dataset to create and evaluate a genetic 428 
classifier using the KNN class prediction method (Table S6). Utilization of this classifier on the cell mi-429 
croarray data correctly classifies 9/9 samples (0 absolute error, 0 ROC error, confidence of prediction of 430 
each sample 0.667). 431 
 432 
In order to evaluate the physiologic context of the transcriptional footprint left by Ala92-D2HY-expres-433 
sion, the microarray data were analyzed by GSEA (29, 30), which revealed 97 gene sets enriched at a 434 
nominal p-value of <1% in Ala92-D2HY- vs. Thr92-D2HY-expressing cells (Table S7). Subsequent investi-435 
gator analysis indicated that a predominance of the genes contained in these sets played a role in NF-κB 436 
signaling, inflammation, lysosome, cell cycle control, DNA repair and cytoskeleton maintenance. 437 
Twenty-nine of these gene sets contain genes involved in cell membrane transport or function (Table S7). 438 
There were 63 gene sets downregulated in Ala92-D2HY-expressing cells that were involved in DNA me-439 
tabolism, cell cycle maintenance, transcription regulation, apoptosis, EGFR signaling and mitochondria 440 
(Table S6). A GSEA-generated heat map of the top 50 genes (up and down) by their ranking criteria was 441 
obtained (Figure 4D). 442 
 443 
Next we tested whether differences between Ala92-D2- versus Thr92-D2 could interfere with TH signal-444 
ing by measuring the expression level of a custom set of typical T3-responsive genes (Table S4) (18, 19) 445 
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and, as in the brains, found no significant differences by GSEA (Fig. S1B). Differences in TH activation 446 
between Ala92-D2- versus Thr92-D2 were also evaluated using a previously characterized co-culture sys-447 
tem (33) where T3-responsive cells were co-cultured with Thr92-D2HY- or Ala92-D2HY-expressing cells. 448 
Here HeLa cells were used as targets as they express two highly sensitive T3-responsive genes, i.e. BCL3 449 
or SPOT14 (34, 35), but no differences in the expression of either gene were observed in co-cultures with 450 
either Thr92-D2HY- or Ala92-D2HY-expressing cells (Fig. S5). 451 
 452 
Are the genes identified in the cells also altered in the human brain samples obtained from Ala92-D2 453 
homozygous donors? 454 
 455 
To that end we generated a list of 40 genes (40-list) identified in the cell microarray GSEA based on their 456 
representation within prominent gene ontology classes and analyzed their expression level in all brain 457 
samples by RT-qPCR. CDK2 expression inversely correlated with the Ala92-D2 allele dose (Fig. 5A) 458 
whereas the opposite was observed for CD24 (Fig. 5B). Next, we combined expression data of Hets and 459 
Ala92-D2 homozygotes to test whether the expression of these 40 genes was indistinctly affected by at 460 
least one copy of the AlaD2 allele. This strategy confirmed that 9 other genes identified in the cells, total-461 
ing 11 genes (11-list), were affected by the AlaD2 allele in the human brain (Fig. 5C). The 40-list was 462 
further analyzed using the fold change ranking approach (36) that yielded 21 genes (7 genes in common 463 
with the 11-list) with expression level that varied >1.5-fold between any two genotypes (Fig. 5D) and 464 
clustered into 5 groups (Fig. 5E).  465 
 466 
Next, we asked whether the expression of any of the genes in the 40-list correlated with the level of D2 467 
expression within each genotype. Using the Pearson correlation analysis we identified 27 genes that sig-468 
nificantly correlated with the D2 mRNA level within samples of each of the three genotypes (Table S8; 469 
Fig. 5F). Notably, only the thyroid hormone transporter gene SLCO1C1 (OATP14) expression correlated 470 
significantly with D2 mRNA independently of genotype (Fig. 5F).  471 
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 472 
Using human brain and cell microarray data to define the Ala92-D2 genetic fingerprint 473 
 474 
Venn diagrams were used to identify common genetic features between human brain and cell microarray 475 
datasets. We first looked at individual genes enriched in the gene sets from cell- (1228 genes) and human 476 
brain- (382 genes) GSEA and identified 79 common genes (79-list) (Fig. 5G). Notably, the gene set for 477 
Epidermal Growth Factor Receptor Signaling Pathway (EGFR) was down-regulated in human brain ho-478 
mozygous for Ala92-D2 and Ala92-D2-expressing cells (Tables S3,S7; Fig. S6). 479 
 480 
Next, a classifier of the 79-list was created and applied to the microarray data sets from the Thr92-D2 and 481 
Ala92-D2 homozygous human brain donors to predict their genotype; all of the Thr92-D2 samples were 482 
correctly classified as well as 5/6 Ala92-D2 samples. When this classifier was strengthened with the addi-483 
tion of two genes identified from a computer-generated weighted voting prediction model, SNORD16 and 484 
TRAPPC4 (Table S2), the 81-gene classifier correctly predicted the genotypes of all homozygous Thr92-485 
D2 and Ala92-D2 human brain samples (0 absolute error, 0 ROC error, confidence of prediction of each 486 
sample 0.028-0.704). We also applied the 81-gene classifier to the data set of all 19 samples to predict 487 
carrier status of at least one allele, which was correct in 18 patients (Absolute error 0.05, ROC error 0.04).  488 
 489 
Oxidative stress plays a role in the genetic fingerprint of Ala92-D2HY-expressing cells 490 
 491 
Next we used the cell model to assess findings obtained in the combined genetic analysis of brain and cell 492 
microarrays, such as Golgi function and oxidative stress (Fig. 1D; Tables S3,S7). We looked at the ex-493 
pression of seven genes affected by the Ala92-D2HY before (Fig. 6A) and after treatment with the chemi-494 
cal chaperone TMAO (minimizes ER stress; Fig. 6B) or the anti-oxidant NAC (Fig. 6C). Here, we also 495 
included a subset of five Golgi apparatus related genes given the ectopic presence of Ala92-D2HY in this 496 
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structure and the finding of three Golgi-specific genes (ATP11B, ABCG1, TRAPPC4) and 15 Golgi-re-497 
lated genes (Fig. 5G) in the 81-gene list. Whereas treatment with TMAO for 24 h normalized expression 498 
of only one of those genes (Fig. 6C), exposure to NAC had a more consistent pattern of abating differ-499 
ences between Ala92-D2HY and Thr92-D2HY-expressing cells in 5 of the 7 genes analyzed, all related to 500 
the Golgi apparatus (Fig. 6C). Notably, the observation that Ala92-D2HY expressing cells exhibit an in-501 
crease in the pre-apoptosis marker Annexin-V (Fig. 6D) also points towards oxidative stress as well as 502 
disruption in the EGFR signaling pathway (37), similar to what was observed in EGFR-/- cortical astro-503 
cytes (38).  504 
 505 
  506 
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Discussion 507 
 508 
A striking observation in the human brain and cell models is that expression of Ala92-D2 interferes with 509 
basic cellular processes in a pattern that establishes an 81-gene fingerprint of transcriptional alterations 510 
related to CNS diseases, ubiquitin and ER stress, mitochondrial dysfunction, inflammation, apoptosis, 511 
DNA repair and growth factor signaling. It is conceivable that the change in the single amino acid pro-512 
duces a protein that upsets basic ER functions triggering ER stress and changes in ubiquitination genes; 513 
the Ala92-D2 ultimately escapes to the Golgi apparatus and disrupts its normal ribbon morphology. Thus 514 
mitochondrial dysfunction, inflammation and apoptosis are likely consequences of primary disruption in 515 
ER and Golgi. The prolonged half-life exhibited by Ala92-D2HY could also be a consequence of its pres-516 
ence in the Golgi, sheltered from the typical proteasomal machinery present in its native ER location. It is 517 
notable that treatment with an anti-oxidant agent normalized the expression of multiple genes affected by 518 
Ala92-D2HY, indicating that oxidative stress plays a role in defining the genetic fingerprint. Thus, it is 519 
plausible that this fingerprint underlies the different clinical phenotypes associated with homozygosity for 520 
Ala92-D2.  521 
 522 
Another striking observation in the present studies was that both native and polymorphic D2 were found 523 
associated with the nuclear compartment in the HEK-293 cells. Of course this could be the result of D2 524 
overexpression in this cell model and final determination awaits the development of high-quality D2 anti-525 
sera to study endogenous D2 expression. If confirmed in vivo, this would explain the decades-old kinetic 526 
and physiological data that D2-generated T3 contributes much to the occupation of TR (39, 40). In the 527 
brain of course, D2 is expressed in glial cells while TR is expressed predominantly in neurons and thus a 528 
higher level of TR occupancy is most likely the result of accelerated local T3 production and signaling 529 
through a paracrine mechanism (33). In any event, that no differences in nuclear D2 were observed be-530 
tween Thr92-D2HY and Ala92-D2HY proteins support the notion that TH signaling is not grossly affected 531 
by this polymorphism (Fig. S3C-D).  532 
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 533 
A strength of the present study is the complementary usage of microarray analysis in brain and cells, 534 
which led to the refinement of the genetic fingerprint initially discovered in the brains. The resulting 81-535 
gene fingerprint was highly efficacious as a genotype classifier in these samples. Along these lines, the 536 
observation that Huntington’s disease was the top pathway identified in the gene analysis of the human 537 
brains indicates similarities between the two diseases might exist. Indeed, Huntington’s is a CNS degen-538 
erative disease that causes chorea and loss of cognition that is caused by huntingtin, an ER-associated 539 
protein that normally translocates to and from the cell nucleus (41). Carriers of the mutant huntingtin gene 540 
express an abnormally long version of the huntingtin protein that is hydrolyzed into smaller peptides that 541 
accumulate and disrupt the normal function of neurons. This leads to ER and oxidative stress, and eventu-542 
ally to apoptosis of neurons in the striatum, explaining the signs and symptoms of Huntington’s disease 543 
(42, 43). While it is too early to draw any definitive conclusions, the parallels between the Huntington’s 544 
disease mechanism and the observations in our Ala92-D2HY cell model are intriguing and could ultimately 545 
indicate that carriers for the D2 variant may be predisposed to neurodegenerative processes. The gene 546 
analyses also point towards alternative disease mechanisms such as disruption of the EGF signaling path-547 
way, which is known for playing a role in cognitive development (12) and impairment in diseases includ-548 
ing Parkinson’s (14, 15), Alzheimer’s (16) and schizophrenia (13). 549 
 550 
It is clear that the clinical phenotypes associated the Ala92-D2 polymorphism are not limited to hypothy-551 
roid patients, but can be traced back to tissues/organs that express D2 (44). However, it is unclear why 552 
hypothyroid carriers of the Ala92-D2 polymorphism would prefer combination therapy with L-T4 and L-553 
T3 (7) given that TH signaling is not affected by Ala92-D2. While much additional investigation is still 554 
needed, it is conceivable that compensatory mechanisms developed in carriers of the Ala92-D2 polymor-555 
phism lose effectiveness in the setting of treatment with L-T4, when patients exhibit an elevation in serum 556 
T4/T3 ratio (45, 46). On this note, D2 mRNA levels in the brain correlate with the TH transporter 557 
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OATP14 (Fig. 5F). Therefore, the present findings do not provide a direct rationale for combination ther-558 
apy with L-T4 and L-T3.  559 
 560 
In conclusion, we have uncovered a unique 81-gene fingerprint left in the brain and in cells expressing 561 
Ala92-D2. This is caused by cellular accumulation of Ala92-D2 that can be found ectopically in the Golgi 562 
apparatus, and is associated with ER and oxidative stress as well as pre-apoptosis. There are striking simi-563 
larities between these findings and changes observed in other well-characterized brain degenerative dis-564 
eases. Future research should clarify whether the disease mechanisms proposed in the present investiga-565 
tion contribute to the phenotype of Ala92-D2 carriers.  566 
 567 
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Figure Legends 706 
 707 
Figure 1. Microarray analysis of human brain from patients homozygous and heterozygous for the 708 
Thr92AlaD2 polymorphism. (A) Volcano plot of expression data in the comparison of Ala92-D2 (n = 6) 709 
and Thr92-D2 (n = 6) homozygotes; highlighted genes are significant at a p-value < 0.05 and a fold 710 
change > 1.3 (red) or < -1.3 (green). Generated in Affymetrix Transcriptome Analysis Console; (B) Heat 711 
map of the 25 most enriched and 25 most down-regulated genes in human brain samples from Ala92-D2 712 
and Thr92-D2 homozygotes by fold change from differential expression analysis; expression values are 713 
represented as colors (red: increased expression; blue decreased expression) with the degree of color satu-714 
ration indicating degree of expression; distinct transcriptional trends are observed; (C) Heat map of the 715 
top 50 features exhibited by polymorphic homozygotes versus normal patients as calculated in the gene 716 
set enrichment analysis software; (D) Canonical pathways identified in analysis of all brain samples (n = 717 
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19) where individual pathways are grouped by overlap in function, each of these pathways was altered at 718 
p<0.05 and with a ratio of genes affected within the pathway >60%.  719 
 720 
Figure 2. Thr92-D2HY and Ala92-D2HY are both found in the nucleus but Ala92-D2HY has a longer 721 
half-life. (A-B) Immunofluorescence of HEK-293 cells stably expressing D2HY proteins; D2 was stained 722 
; (C) the indi-723 
cated cells were incubated for 40-120 min with 100 uM CHX and subsequently harvested and processed 724 
Actin; (D) quantification of the bands shown in C; data were ana-725 
lyzed by non-linear regression assuming that D2 decays exponentially after addition of CHX; all data are 726 
the mean ± SEM of 3 entries per data-point; (E-F) immunofluorescent detection of plasma membrane by 727 
the Na+/K+-ATPase (red) and αYFP of D2HY fusion proteins (green) in the same cells as A-B before 728 
(above) and after (below) treatment with CHX for 120 min; (G) electron microscopy of HEK-293 cells 729 
 32 
stably expressing D2HY proteins as in A-B; silver grains denoting D2HY can be visualized in the rough en-730 
doplasmic reticulum (arrows) in both Thr92-D2HY and (H) Ala92-D2HY-expressing cells; (I) the nucleus 731 
also contains Thr92-D2HY and (J) Ala92-D2HY proteins; scale bars = 0.25 um.  732 
  733 
Figure 3. Ala92-D2HY, but not Thr92-D2HY, can be found in the Golgi. (A) Electron microscopy of 734 
Thr92-D2HY expressing cells where a typical Golgi apparatus is devoid of D2 protein; (B-C) same as A 735 
except that Ala92-D2HY expressing cells were studied; in this case, silver grains denoting the presence of 736 
Ala92-D2HY protein are observed associate to the Golgi apparatus (arrow); scale bars = 0.25 um; (D) Im-737 
munofluorescence staining of Thr92-D2HY and (E) Ala92-D2HY (green) expressing cells with cis-Golgi 738 
marker GM-130 (red). White box is enlarged in green (D2) and red (GM-130) channels. Yellow arrows 739 
show Thr92-D2HY and Ala92-D2HY specific cis-Golgi staining features, where Ala92-D2HY Golgi demon-740 
strates a circular morphology compared to the ribbon configuration in the Thr92-D2HY-expressing cells; 741 
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(F) The circularity index of the cis-Golgi complex in individual D2HY-expressing cells was measured in 742 
ImageJ where the cis-Golgi structure in Ala92-D2HY cells had higher circularity values than from Thr92-743 
D2HY cells; (G-I, M-O) Untreated cells display the typical appearance of Golgi-complex independently 744 
from the type of D2 expressed in the cells. The cisternae of the Golgi complex were organized in parallel, 745 
slightly curved and surrounded by small Golgi vesicles; (J-L) In cells expressing the Thr92-D2HY, BFA 746 
treatment (0.5 µg/ml) resulted in a disorganization of the Golgi apparatus with scattered, dilated and short 747 
cisternae. However, some organized Golgi can be observed; (P-R) In BFA-treated Ala92D2HY-expressing 748 
cells, circular Golgi complexes were present that were otherwise unidentified in Thr92-D2HY expressing 749 
cells.  750 
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Figure 4. Microarray analysis of HEK-293 cells stably expressing Ala92-D2HY or Thr92-D2HY pro-754 
teins. (A) Volcano plot of expression data in the comparison of Ala92-D2HY (n = 3) with Thr92-D2HY -755 
expressing cells (n = 3); highlighted genes are significant at a p-value < 0.05 and a fold change > 1.3 (red) 756 
or < -1.3 (green); (B) cultured cells differing only in their stable expression of Ala92-D2HY versus Thr92-757 
D2 HY have unique transcriptional features where heat mapping of the 25 most enriched and 25 most 758 
downregulated genes as identified by fold change calculated in differential expression analysis are shown; 759 
(C) dendogram created via hierarchical clustering analysis reveals that mRNA expression patterns of 760 
Thr92-D2, Ala92-D2 and YFP-expressing cells cluster with samples of the same phenotype; Ala92-D2 761 
cells exhibit a transcriptional expression pattern more similar to Thr92-D2-expressing cells than to YFP 762 
controls; (D) heat map of the top 50 genes up- and down-regulated genes as ranked by gene set enrich-763 
ment analysis software. 764 
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Figure 5. Identification of genes differentially affected by Ala92-D2 expression in both cells and hu-766 
man brains. 40 genes identified in the cell microarray (i) for their significant alteration in expression and 767 
(ii) representation of unique physiologic themes were chosen for additional studies in human brain. (A) 768 
Relative expression of CDK2 by RT-qPCR in human brain samples from Ala92-D2 and Thr92-D2 homo-769 
zygotes and heterozygous; (one-way ANOVA p = 0.01, two-tailed t test Ala92-D2 vs. Thr92-D2, p = 770 
0.02); (B) same as A except that CD24 was studied; (one-tailed t test Ala92-D2 vs. Thr92-D2, p = 0.05); 771 
(C) when expression data from heterozygous and homozygous samples were combined, significant differ-772 
ences in comparison to Thr92-D2 brain samples was observed for 9 genes; (D) 21 genes exhibited an ex-773 
pression level that varied >1.5-fold between any two genotypes; these 21 genes are depicted in a Venn 774 
diagram to show genes identified in one or more pairwise genotype comparisons; (E) hierarchical cluster-775 
ing of these genes (aside from DIO2) after normalization to the expression level of Thr92-D2 homozy-776 
gotes using Euclidean distance metric yields a dendogram showing 5 clusters; expression levels are indi-777 
cated by heatmap (low: blue; high: red) created in Agilent Genespring GX 12.6; (F) D2 expression in hu-778 
man brain correlated significantly (Pearson correlation at p<0.05) with the expression of 27 genes; Venn 779 
diagram showing overlap between genes that correlated with D2 in Thr92-D2 homozygotes, Hets and 780 
Ala92-D2 homozygotes samples; (G) 79 individual genes common to both the cell and human brain mi-781 
croarray gene set enrichment analyses were identified using Venn diagrams, constituting the Ala92-D2 782 
fingerprint; these include two Golgi-specific genes (red) and 15 Golgi-related genes (bold). 783 
 36 
 784 
Figure 6. Normalization of gene expression profile in Ala92-D2 expressing-cells by antioxidant and 785 
the chemical chaperone NAC. (A) Expression levels of genes identified in cell microarray were con-786 
firmed by RT-qPCR in Thr92-D2HY- and Ala92-D2HY-expressing cells where selected genes exhibited 787 
lower expression levels in Ala92-D2HY; (B) Treatment with chemical chaperone, trimethylamine oxide 788 
(TMAO), normalizes two genes; (B) After 24 h of treatment with N-acetylcysteine (NAC), the expression 789 
levels of the Golgi-related genes normalized with respect to their expression levels in Thr92-D2HY-ex-790 
pressing cells; (two-tailed t tests *p≤0.05, *** p≤0.001, ****p≤0.0001, all data are the mean ± SEM of 3 791 
entries per data-point); (D) The early stage of apoptosis was examined by annexin V/propidium iodide 792 
staining of intact cells; cells were gated per YFP signal, annexin V-PE/propidium iodide were FL2/FL3. 793 
Left two panels are annexin V-PE staining where M1 represents non-apoptotic cells and M2 represents 794 
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apoptotic cells; right two panels are propidium iodide staining to differentiate late-apoptotic from necrotic 795 
cells. 796 
 797 
Supplementary Figure Legends 798 
 799 
Figure S1. Ala92-D2 homozygous brain samples and Ala92-D2HY-expressing cells do not exhibit 800 
transcriptional evidence of hypothyroidism. (A) The complete microarray dataset for all 12 Ala92-D2 801 
and Thr92-D2 homozygous brain samples was analyzed by gene set enrichment analysis (GSEA) using a 802 
custom gene set of known T3-responsive genes (18, 19) (Table S4). Enrichment plot and heat map, both 803 
generated in GSEA (Broad Institute), demonstrate enrichment patterns for this custom gene set where the 804 
gene set was not found to be enriched (nominal p-value 0.835, FDR 0.842); (B) Also, this T3-responsive 805 
Ala92			Thr92	Ala92				Thr92	
Supplemental	Figure	1	
A	 B	
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custom gene set was not enriched in the Ala92-D2 vs. Thr92-D2 cell microarray (nominal p-value 0.604, 806 
FDR 0.701). 807 
 808 
Figure S2. HEK-293 cells stably expressing Ala92-D2HY exhibit normal growth and division (A) Cell 809 
size was analyzed by distribution of forward scatter signal from FACS instrument; (B) Two forward scat-810 
ter distribution curves from Thr92-D2HY and Ala92-D2HY were superimposed for comparison; (C) Cell 811 
cycle was analyzed by propidium iodide staining after fixation. M1, M2, M3, M4 region denotes subG1, 812 
G0/G1, S, G2/M stages of cell cycle respectively; (D) Cell growth was analyzed by counting cells after 813 
plating. 814 
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 815 
Figure S3. Ala92-D2HY lingers after exposure to T4. (A) Thr92-D2HY and Ala92-D2HY cells were incu-816 
bated for 120 min with three different conditions, stripped serum (SS, which has no T4), normal fetal bo-817 
vine serum (NS) and 100 M T4 with fetal bovine serum and subsequently harvested and processed for 818 
Tubulin. Whereas Thr92-D2HY decreases in response to T4, its natu-819 
ral substrate, Ala92-D2HY levels decrease only slightly suggesting impaired degradation via ubiquitina-820 
tion; (B) Thr92-D2HY and Ala92-D2HY cells were incubated for 120 min with 100 uM T4 and subse-821 
quently harvested and processed for wes Tubulin; data from 3 independ-822 
ent experiments were pooled; (C) the indicated cells were incubated for 20-120 min with 100 uM CHX 823 
and subsequently harvested and processed for western analysis of D2HY proteins in cell lysates or in nu-824 
clear fractions ) D2 activity of isolated nuclear fractions after treatment with 825 
CHX; values are the mean ± SEM of 5 entries per data-point; (E-F) immunofluorescence of HEK-293 826 
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cells stably expressing D2HY 827 
ER, nuclei were stained with DAPI (blue), and overlap with nuclear lamin (red) is also visualized. 828 
 829 
Figure S4. Only Ala92-D2HY can be found in the Golgi apparatus after treatment with cyclo-830 
heximide. (A) Thr92-D2HY cells treated with CHX (100 μg/ml) for 2 hours lack silver grains denoting 831 
localization of D2HY within the Golgi apparatus (arrows indicate Golgi); (B,C) Ala92-D2HY can be read-832 
ily visualized within the Golgi apparatus in CHX-treated cells; scale bars = 0.25 μm. 833 
Supplemental	Fig.	4	
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 834 
Figure S5. Expression of T3-responsive genes in HeLa cells co-cultured with Thr92-D2HY or Ala92-835 
D2HY-expressing cells did not differ. When HeLa cells were grown in a previously characterized co-cul-836 
ture system(33) with Thr92-D2HY- (n = 6) or Ala92-D2HY-expressing (n = 6) cells, no differences in the 837 
expression of either T3-responsive gene were observed (BCL3: p-value 0.33, two-tailed t test; SPOT14: 838 
p-value 0.42, two-tailed t test). 839 
 42 
 840 
Figure S6. 50/56 Genes within the EGF Signaling Canonical Pathway are Altered in Human Brains. 841 
When pathway analysis was performed on the complete microarray dataset from human brain samples 842 
from Ala92-D2 homozygotes, Hets, and Thr92-D2 homozygotes (n = 19), the EGF Signaling pathway 843 
diffuse alterations in genes within this pathway were identified (p-value < 0.001, ratio 50/56) from the 844 
receptors themselves to downstream signaling molecules. 845 
 846 
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